Questions and Answers About the COVID-19 Vaccine Study
- Adults 18 years and older.
- Healthy or have medically-stable chronic diseases.
- Medically stable means you can have a chronic condition like diabetes, high blood pressure, etc., as long as you are being treated for it and it is stable.
- Do not have a previously confirmed diagnosis of COVID-19.
Approximately 33,000 participants from all over the country will be enrolled.
The first 3,000 volunteers will be enrolled in a sub-study looking to see if the vaccine provokes an immune response and to see if the vaccine causes expected reactions like fever, bruising/swelling, or soreness near the injection site.
No. This investigational vaccine is made of a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2.
What does that mean?
The investigational vaccine uses a weakened form of a cold virus only found in chimpanzees, that makes one of the COVID-19 virus proteins.
Recipients of the investigational vaccine don’t have any guaranteed benefit, however, the study may prove the vaccine to be effective and may offer participants protection from COVID-19.
The information gained from this study will help determine if this investigational vaccine is a safe and effective way to prevent COVID-19 and help decide if it should be made and distributed widely.
Learn More and Volunteer
Visit the COVID-19 vaccine trial page on UMHealthResearch.org to discover if you are eligible and learn more about the trial.
Visit UMHealthResearch.org to learn more about other coronavirus-related clinical research studies at the University of Michigan.
Reach out to the study team at AZVaccineStudy@med.umich.edu.